Insider · CIK 0001553594
Corey N. Fishman
Files at ITRM (Iterum Therapeutics plc). First filing Nov 20, 2023, latest Nov 20, 2023.
In brief
Corey N. Fishman files SEC Form 4 as CEO and director at ITRM (Iterum Therapeutics plc). Since Nov 20, 2023, Corey N. Fishman has reported 1 open-market buy worth $16k and 0 open-market sells worth $0, the latest filed on Nov 20, 2023.
A track record needs three past buys with six months of prices behind them; Corey N. Fishman has 0, so none is measured yet.
The newest scored trade: bought $16k of ITRM on Nov 20, 2023, filed Nov 20, 2023, scored 39 (weak).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 39Weak | Iterum Therapeutics plc | $16k 10,000 shares | +22% | - |
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 20, 2023 | ITRM Iterum Therapeutics plc | POpen-market purchase Ordinary Shares | +10,000 | $1.59 | $16k | 54,449 | Nov 20, 2023 |
Questions about Corey N. Fishman
Answered from the filings on this page, as of the latest one.
Is Corey N. Fishman buying or selling?
Not in the last 12 months. Corey N. Fishman's latest open-market trade on SEC Form 4 was bought $16k of ITRM on Nov 20, 2023.
How did Corey N. Fishman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Corey N. Fishman has 0.
Where does Corey N. Fishman file Form 4?
Corey N. Fishman has filed Form 4 at ITRM (Iterum Therapeutics plc) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.